Abstract:The complexity of cancer requires a comprehensive approach to understand its diverse manifestations and underlying mechanisms. The Research Topic begins with the perspective article Senga et al. highlighting the need to integrate clear endpoints that anchor KCCs to the acquisition of a complete malignant phenotype into chemical testing. Thus, an allencompassing strategy that incorporates both evolving KCCs and cancer hallmarks, including the role of the microenvironment, is essential to enable the targeted identification of prevalent carcinogens and facilitate zone-specific prevention strategies. To achieve this goal, collaboration between the KCCs and cancer hallmark communities becomes essential.Schroeder et. al. demonstrated that environmental chemicals with established exposure disparities between non-Hispanic Black women and non-Hispanic White women may influence breast phenotypic plasticity, a new hallmark of cancer. This type of plasticity is associated with basal-like breast cancers typically associated with an aggressive triple-negative subtype which affects African American women at rates of 2-3 times that of White women. These data were largely generated with a high-content imaging microscope demonstrating that innovative techniques will bring us closer to understanding cancer disparities at a molecular level. In addition, to better address and understand breast cancer disparities, it is also important to understand risk among different races. Most epidemiological studies have been performed on non-Hispanic White women. Original research by Patil et. al. studied benign breast disease and the subsequent development of breast cancer in African American women.The identification of extracellular vesicles (EVs) in vivo holds potential for the discovery of early biomarkers of carcinogenesis, and/or toxicity endpoints. EVs from donor cells communicate with recipient cells and/or tissues and have the potential to induce toxicity or promote tumorigenesis. However, much of what is currently known about EVs is from studies that perform exogenous administration. A perspective by Nambiar et. al. reviews methodologies that track and alter EVs directly in vivo, as they are released by donor cells. The authors make the argument that advancements in EV engineering with mouse transgenesis and modern sequencing technologies may provide more insight into this largely unknown area of native EV function and biology. A perspective article by Silver et. al. highlights the significance of detecting and characterizing circulating EVs as biomarkers for chemotherapy-induced cardiotoxicity. There are current capabilities to characterize circulating EVs in mice and human liquid cohorts for translational toxicology and cancer medicine.The perspective article by Hariharan et. al. discusses the significance of using human datadriven approaches to improve wellness and reduce tumor recurrence in cancer survivors. Regaining wellness is challenging due to the presence of a myriad of issues induced by radiation, chemotherapy, immunotherapy and/or targeted interventions. This perspective provides promising evidence that global interventions may be possible with data-driven approaches coupled to quality of life and cognitive measurements as well as biological age measurements.Two original articles examined molecular and carcinogenic effects of a chemical exposure. Carswell et al. used targeted templated Oligo-sequencing and DNA methylation profiles on a genome-wide scale to identify DNA methylation alterations with early-in-life dichloroacetic acid (DCA) exposure to determine potential mechanisms of liver tumorigenesis. This question arose from previous paradoxical findings whereby DCA exposure shunted cellular metabolism from aerobic glycolysis, which is termed the Warburg Effect and is associated with cancer, to oxidative phosphorylation. Gonzalez-Pons et al. examined the interactions between a high-fat diet and benzo(a)pyrene on tumorigenesis in an aggressive mouse model of estrogen receptor negative breast cancer.Cohen provides a comprehensive review of the different modes of action of chemical carcinogenesis and how to screen for human carcinogens using the primary endpoints of DNA reactivity and mutagenesis, immunomodulation, increased estrogenic activity, and cytotoxicity with consequent regeneration. Mechanistic understanding of chemical carcinogenicity and hazard identification will be critical for prevention of future cancers.In conclusion, cancer prevention strategies will significantly contribute to reaching the goal of the White House Cancer Moonshot Initiative of decreasing 50% cancer mortality by the year 2047 (6). This can be only achieved by bringing together novel ideas, multidisciplinary efforts, and cutting-edge technologies. Hence, this Research Topic provides a collection of articles that will encourage further research and collaborative efforts in the fields of mo -Abstract Truncated-

Special Issue "Cancer Biomarker Research and Personalized Medicine 2.0"

Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics"

Editorial for the Special Issue "Advances in the Development of Anticancer Drugs"

Blueprint for cancer research: Critical gaps and opportunities

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Biomarkers for personalized oncology: recent advances and future challenges

Proteomics, Personalized Medicine and Cancer

Editorial: Reviews in breast cancer: 2023

Editorial: Furthering precision medicine and cancer prevention through novel insights in molecular and chemical carcinogenesis

Personalized medicine: Clinical oncology on molecular view of treatment

Clinical cancer genomics and personalized treatment

Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective

Personalized Medicine: Recent Progress in Cancer Therapy

Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress

Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Biomarkers, Bundled Payments, and Colorectal Cancer Care.

Special issues and current controversies

Traditional Medicine in Cancer: What is New in 2022

Biomarkers for early cancer detection: A landscape view of recent advancements, spotlighting pancreatic and liver cancers

A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges